US Tox21 to begin screening 10,000 chemicals

December 7, 2011 in Other

A high-speed robotic screening system, aimed at protecting human health by improving how chemicals are tested in the United States, begins today to test 10,000 compounds for potential toxicity. The compounds cover a wide variety of classifications, and include consumer products, food additives, chemicals found in industrial processes, and human and veterinary drugs. A complete list of the compounds is publicly available at http://www.epa.gov/ncct/dsstox.

Testing this 10,000 compound library begins a new phase of an ongoing collaboration between the National Institutes of Health, the U.S. , and the U.S. , referred to as Tox21. NIH partners include the National Toxicology Program (NTP), administered by the National Institute of (NIEHS), and the NIH Genomics Center (NCGC), part of the NIH Center for Translational Therapeutics (NCTT), housed at the National Institute (NHGRI).

"There has never been a compound library like this before," said NIEHS/NTP Director Linda Birnbaum, Ph.D.

Birnbaum is especially excited that some of the compounds the NTP has brought forward for testing are mixtures of chemicals. "All of us are exposed to many different chemicals at the same time, not just one chemical at a time," she said. "These new technologies allow us to more rapidly advance our understanding of not only individual chemicals, but mixtures of chemicals as well."

A subset of the NTP portion of the 10,000 compound library will focus on pilot testing several formulations or mixtures of compounds, a priority area for NIEHS/NTP. The library constituents were selected after a thorough analysis of existing scientific studies, more than 200 public chemical databases, and chemical nominations received from internal and external partners. Each test compound will undergo a thorough chemical analysis to verify its identity and determine its purity, concentration, and stability.

The goal of the testing is to provide results that will be useful for evaluating if these chemicals have the potential to disrupt processes in the human body to an extent that leads to adverse health effects.

The compounds will be tested in the Tox21 robotic screening system at the NCGC in Rockville, Md. The Tox21 robot, unveiled earlier this year, was purchased with funds provided by the NTP as part of its contribution to the Tox21 partnership.

"The robot has undergone rigorous testing since it was installed and unveiled earlier this year. It's ready to start testing this large compound library," said NHGRI Director Eric Green, M.D., Ph.D. "This is a milestone for Tox21, because it will allow us to test chemicals at a rate previously impossible for anyone to do by hand."

The development of methods for evaluating chemical toxicity has the potential to revolutionize the assessment of new environmental chemicals and the development of new drugs for therapeutic use.

"We are happy to contribute NCGC's pharmaceutical collection of approximately 3,500 compounds of approved and investigational drugs as part of the Tox21 program," said NCTT Scientific Director Christopher Austin, M.D. "Drug toxicity is one of the primary reasons that the development of new drugs fails and approved drugs are removed from the market, and the ability to better predict toxicity would improve the efficiency of drug development enormously."

The EPA seeks to understand the molecular basis of such chemicals to better protect human health and that of the environment.

"The Tox21 partnership integrates revolutionary advances in molecular biology, chemistry, and computer science, to quickly and cost-effectively screen the thousands of chemicals in use today," said Paul Anastas, Ph.D., assistant administrator of the EPA Office of Research and Development. "The innovative robotics screening technology will generate chemical toxicity data that EPA has never had before."

The FDA, also a partner in Tox21, emphasizes the value of this effort for the public. "The Tox21 rapid assessment of drug toxicity can become a powerful safety tool for protecting the American public. It also has the potential to help bring innovative drugs to market by allowing drug developers to identify unsafe candidate drugs early," said Janet Woodcock, M.D., director of the FDA Center for Drug Evaluation and Research.

More information: All testing results will be available to the public through NIH and EPA chemical toxicity databases. In addition, NCTT has created a Tox21 chemical inventory browser freely available at http://tripod.nih. … ov/tox21chem to provide researchers with additional about the chemicals. For more information about Tox21, visit http://www.niehs.nih.gov/health/assets/docs_p_z/ntp-tox21.pdf

Provided by National Institutes of Health

not rated yet  

Rank not rated yet
Relevant PhysicsForums posts

More news stories

Transvaginal mesh op restores pelvic organ prolapse at price

(HealthDay) -- Transvaginal mesh (TVM) procedures are effective for anatomical restoration of pelvic organ prolapse (POP), but patients report a worsening of sexual function following surgery, according to ...

Other created 11 hours ago | popularity not rated yet | comments 0

Tongue analysis software uses ancient Chinese medicine to warn of disease

For 5,000 years, the Chinese have used a system of medicine based on the flow and balance of positive and negative energies in the body. In this system, the appearance of the tongue is one of the measures used to classify ...

Other created May 25, 2012 | popularity 1 / 5 (1) | comments 0 | with audio podcast

Neck strength, cervical spine mobility don't predict pain

(HealthDay) -- Neither isometric neck muscle strength nor passive mobility of the cervical spine, two physical capacity parameters found to be associated with neck pain in other studies, predicts later neck ...

Other created May 25, 2012 | popularity not rated yet | comments 0

Pool access for the disabled sparks controversy

(AP) -- The Obama administration is sidestepping an election-year confrontation with the hotel industry and other pool owners to give them more time to comply with access rules for the disabled.

Other created May 25, 2012 | popularity not rated yet | comments 0

Chile to cover sex change operations

Chile will soon cover sex change surgeries under its public health plan in order to allow citizens of limited means to "recover their true sexual identity," Health Minister Jaime Manalich said.

Other created May 25, 2012 | popularity not rated yet | comments 0


Keep food safety in mind this memorial day weekend

(HealthDay) -- Picnics, parades and cookouts are as much a part of Memorial Day weekend as tributes to the United States' war veterans.

Travel to high altitudes tied to Crohn's, colitis flare-ups

(HealthDay) -- People with inflammatory bowel disease, which includes Crohn's disease and colitis, may be at increased risk for flare-ups when they fly or travel to high altitudes for skiing or mountain climbing, ...

Family history of Alzheimer's affects functional connectivity

(HealthDay) -- Cognitively normal individuals with a family history of late-onset Alzheimer's disease (AD) may display lower resting state functional connectivity in the default mode network (DMN) of the brain, ...

Of mice and mental models: Neuroscientific implications of risk-optimized behavior in the mouse

(Medical Xpress) -- Regardless of an organism’s biological complexity, every encephalized animal continuously makes under-informed behavioral choices that can have serious consequences. Despite its ubiquity, ...

Weight struggles? Blame new neurons in your hypothalamus

New nerve cells formed in a select part of the brain could hold considerable sway over how much you eat and consequently weigh, new animal research by Johns Hopkins scientists suggests in a study published in the May issue ...

Thioridazine kills cancer stem cells in human while avoiding toxic side-effects of conventional cancer treatments

A team of scientists at McMaster University has discovered a drug, thioridazine, successfully kills cancer stem cells in the human while avoiding the toxic side-effects of conventional cancer treatments.